These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 6604123)

  • 1. Human platelet activation by C3a and C3a des-arg.
    Polley MJ; Nachman RL
    J Exp Med; 1983 Aug; 158(2):603-15. PubMed ID: 6604123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demonstration of a specific C3a receptor on guinea pig platelets.
    Fukuoka Y; Hugli TE
    J Immunol; 1988 May; 140(10):3496-501. PubMed ID: 3283237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study on biological activities of various anaphylatoxins (C4a, C3a, C5a). Investigations on their ability to induce platelet secretion.
    Meuer S; Hugli TE; Andreatta RH; Hadding U; Bitter-Suermann D
    Inflammation; 1981 Dec; 5(4):263-73. PubMed ID: 6976935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3a induced activation and stimulus specific reversible desensitization of guinea pig platelets.
    Zanker B; Rasokat H; Hadding U; Bitter-Suermann D
    Agents Actions Suppl; 1982; 11():147-57. PubMed ID: 6983827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of platelet aggregation by the complement-derived peptides C3a and C5a.
    Grossklaus C; Damerau B; Lemgo E; Vogt W
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Oct; 295(1):71-6. PubMed ID: 1004644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet-serotonin release by C3a and C5a: two independent pathways of activation.
    Meuer S; Ecker U; Hadding U; Bitter-Suermann D
    J Immunol; 1981 Apr; 126(4):1506-9. PubMed ID: 7204973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternate complement pathway induction of aggregation and release of 5-hydroxytryptamine and adenosine diphosphate by rabbit platelets.
    Marney SR; Colley DG; Des Prez RM
    J Immunol; 1975 Feb; 114(2 Pt 1):696-703. PubMed ID: 804512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaphylatoxin-induced neutrophil chemotaxis and aggregation. Limited aggregation and specific desensitization induced by human C3a and synthetic C3a octapeptides.
    Nagata S; Glovsky MM; Kunkel SL
    Int Arch Allergy Appl Immunol; 1987; 82(1):4-9. PubMed ID: 3492446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the N-terminal regions of hog C3a, C5a and C5a-desArg in their biological activities.
    Damerau B; Zimmermann B; Czorniak K; Wüstefeld H; Vogt W
    Mol Immunol; 1986 Apr; 23(4):433-40. PubMed ID: 3487713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The human complement system in thrombin-mediated platelet function.
    Polley MJ; Nachman R
    J Exp Med; 1978 Jun; 147(6):1713-26. PubMed ID: 681879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement activation and polymorphonuclear neutrophil leukocyte elastase in sepsis. Correlation with severity of disease.
    Gardinali M; Padalino P; Vesconi S; Calcagno A; Ciappellano S; Conciato L; Chiara O; Agostoni A; Nespoli A
    Arch Surg; 1992 Oct; 127(10):1219-24. PubMed ID: 1417490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the interaction of human C5a and C5a des Arg with human monocytes and neutrophils: flow cytometric and chemotaxis studies.
    Yancey KB; Lawley TJ; Dersookian M; Harvath L
    J Invest Dermatol; 1989 Feb; 92(2):184-9. PubMed ID: 2493055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunologic defense mechanism of complement-derived inflammatory chemical mediators].
    Yamamoto T; Kambara T
    Nihon Rinsho; 1988 Sep; 46(9):1974-80. PubMed ID: 3266512
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of classical anaphylatoxin as the des-Arg form of the C5a molecule: evidence of a modulator role for the oligosaccharide unit in human des-Arg74-C5a.
    Gerard C; Hugli TE
    Proc Natl Acad Sci U S A; 1981 Mar; 78(3):1833-7. PubMed ID: 6940191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary injury induced by C3a and C5a anaphylatoxins.
    Stimler NP; Hugli TE; Bloor CM
    Am J Pathol; 1980 Aug; 100(2):327-48. PubMed ID: 6967702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement activation and vascular injury in systemic lupus erythematosus.
    Abramson S; Belmont HM; Hopkins P; Buyon J; Winchester R; Weissmann G
    J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():43-6. PubMed ID: 2886660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microvascular effects of anaphylatoxins C3a and C5a.
    Björk J; Hugli TE; Smedegård G
    J Immunol; 1985 Feb; 134(2):1115-9. PubMed ID: 3871207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a.
    Inagi R; Miyata T; Maeda K; Sugiyama S; Miyama A; Nakashima I
    Immunol Lett; 1991 Jan; 27(1):49-52. PubMed ID: 2019419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Removal of extraplatelet Na+ eliminates indomethacin-sensitive secretion from human platelets stimulated by epinephrine, ADP, and thrombin.
    Connolly TM; Limbird LE
    Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5320-4. PubMed ID: 6577431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement activation and anaphylatoxin (C3a and C5a) formation in preeclampsia and by amniotic fluid.
    Haeger M; Bengtson A; Karlsson K; Heideman M
    Obstet Gynecol; 1989 Apr; 73(4):551-6. PubMed ID: 2784554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.